HONG KONG -- (Marketwire) -- 02/10/12 -- Today, www.EquityLeader.com introduced research coverage of Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) and Qiagen NV (NASDAQ: QGEN). Full research reports are available to readers at: www.EquityLeader.com/index.php?sm1=ONXX&sm2=QGEN.
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Equity Leader has decided to cover Onyx Pharmaceuticals, Inc. for its current position within the healthcare industry. Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company's collaborators, Bayer HealthCare Pharmaceuticals Inc. A copy of this report detailing Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) is available at: www.EquityLeader.com/index.php?sm1=ONXX.
Equity Leader is also taking note of Qiagen NV for its changing role within the services industry. QIAGEN N.V. is a holding company, which provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. To download free research on Qiagen NV (NASDAQ: QGEN) investors may visit: www.EquityLeader.com/index.php?sm2=QGEN.
About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.